2024
Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging
Feher A, Bednarski B, Miller R, Shanbhag A, Lemley M, Miras L, Sinusas A, Miller E, Slomka P. Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266761. PMID: 38548351, PMCID: PMC11064832, DOI: 10.2967/jnumed.123.266761.Peer-Reviewed Original ResearchConceptsMyocardial perfusion imagingHF hospitalizationHeart failureStress left ventricular ejection fractionPerfusion imagingHF exacerbationPredictive of HF hospitalizationsSPECT/CT myocardial perfusion imagingMyocardial perfusionInternational cohortAcute heart failure exacerbationMedian follow-upVentricular ejection fractionReceiver-operating-characteristic curveClinical risk factorsHeart failure exacerbationExternal validation cohortAcute HF exacerbationPrevent HF hospitalizationsImaging parametersCalcium scoreEjection fractionClinical parametersCT scanValidation cohort
2021
Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use
Wendt FR, Koller D, Pathak GA, Jacoby D, Miller EJ, Polimanti R. Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clinical Pharmacology & Therapeutics 2021, 110: 777-785. PMID: 33837531, PMCID: PMC8376807, DOI: 10.1002/cpt.2260.Peer-Reviewed Original ResearchConceptsLDL-C concentrationsSimvastatin useLow-density lipoprotein cholesterol concentrationsLipoprotein cholesterol concentrationsDrug-metabolizing enzymesElectronic medical recordsStatin therapyStatin treatmentActivity scoreMedical recordsPilot cohortCholesterol concentrationsEuropean ancestry participantsMetabolizer phenotypeClinical decisionNAT2 allelesPolygenic riskNAT2Good responseUK BiobankBiological mechanismsPharmacogenesAssociationPotential benefitsPhenotype
2020
Quantification of myocardial blood flow (MBF) and reserve (MFR) incorporated with a novel segmentation approach: Assessments of quantitative precision and the lower limit of normal MBF and MFR in patients
Liu H, Thorn S, Wu J, Fazzone-Chettiar R, Sandoval V, Miller EJ, Sinusas AJ, Liu YH. Quantification of myocardial blood flow (MBF) and reserve (MFR) incorporated with a novel segmentation approach: Assessments of quantitative precision and the lower limit of normal MBF and MFR in patients. Journal Of Nuclear Cardiology 2020, 28: 1236-1248. PMID: 32715416, DOI: 10.1007/s12350-020-02278-y.Peer-Reviewed Original Research
2019
Myocardial Ischemic Burden and Differences in Prognosis Among Patients With and Without Diabetes: Results From the Multicenter International REFINE SPECT Registry
Han D, Rozanski A, Gransar H, Sharir T, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, Di Carli M, Liang JX, Hu LH, Germano G, Dey D, Berman DS, Slomka PJ. Myocardial Ischemic Burden and Differences in Prognosis Among Patients With and Without Diabetes: Results From the Multicenter International REFINE SPECT Registry. Diabetes Care 2019, 43: 453-459. PMID: 31776140, PMCID: PMC6971784, DOI: 10.2337/dc19-1360.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableCohort StudiesCoronary Artery DiseaseDiabetes MellitusDiabetic AngiopathiesFemaleHumansMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaMyocardial Perfusion ImagingPrevalencePrognosisPropensity ScoreRegistriesRisk FactorsTomography, Emission-Computed, Single-PhotonConceptsMajor adverse cardiovascular eventsTotal perfusion deficitMACE riskMyocardial ischemic burdenAdverse cardiovascular eventsTomography myocardial perfusionREFINE SPECT registrySingle photon emissionIschemic burdenMinimal ischemiaCardiovascular eventsCause mortalityLate revascularizationPrognostic impactUnstable anginaSignificant ischemiaPerfusion deficitsMyocardial infarctionMyocardial ischemiaRisk factorsCardiovascular diseaseHigh riskMyocardial perfusionPatientsDiabetes
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairment